AMERICAN HOME PRODUCTS MUST SELL ITS DIPHTHERIA AND TETANUS VACCINES, LICENSE CYANAMID's ROTAVIRUS VACCINES TO MERGE; FTC ORDER APPROVED 4-0
Executive Summary
The American Home Products Nov. 10 consent agreement reached with the Federal Trade Commission regarding AHP's acquisition of American Cyanamid requires the pharmaceutical conglomerate to divest two of its vaccine programs and one vaccine under development by Cyanamid's Lederle Labs. The consent agreement allows AHP to proceed with the merger with Cyanamid announced in August for $9.7 bil. ("The Pink Sheet" Aug. 22, p. 6).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth